Nasus Pharma Ltd. Ordinary Shares (NSRX)
Stock · AMEX · Health Care
$3.24as of 10/16/2026
Price chart
Active signals
Support level
$2.94
Industry
Biotechnology: Pharmaceutical Preparations
About NSRX
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Nalo…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 7
- Website
- www.nasuspharma.com
Fundamentals
- 1-day range
- $3.05$3.18
- Market cap
- $39.70M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-0.87
- Dividend yield
- —
- Beta
- 1.65
- Avg. volume
- 16.3K
52-week range
$1.98$9.5
Forecasts
3 analyst ratings
Buy 88%
Hold 13%
Sell 0%
1-year price forecast
High
$22
+579.0%
Median
$19
+486.4%
Low
$18
+455.6%
Nasus Pharma Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- NSRXNasus Pharma Ltd. Ordinary Shares$3.18▲ 0.47%Market cap $39.70MP/E —$1.98$9.5
- RADXRadiopharm Theranostics Limited American Depositary Shares$1.03▼ 4.63%Market cap $40.11MP/E —$0.0035$0.037
- HYPDHyperion DeFi Inc. Common Stock$2.84▼ 9.84%Market cap $40.47MP/E 7.24$2.34$9.13
- PDSBPDS Biotechnology Corporation Common Stock$1.13▼ 13.08%Market cap $41.78MP/E —$0.1952$1.79
- APLMApollomics Inc. Class A Ordinary Shares$21.1▲ 0.48%Market cap $37.33MP/E —$10.01$42.12
- CRVOCervoMed Inc. Common Stock$2.24▼ 0.44%Market cap $37.33MP/E —$2.13$10
- IXHLIncannex Healthcare Inc. Common Stock$2.82▼ 2.08%Market cap $37.21MP/E —$2.49$14.91
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NSRX Nasus Pharma Ltd. Ordinary Shares | $39.70M | — | $3.18 | ▲ 0.47% | $1.98$9.5 |
| RADX Radiopharm Theranostics Limited American Depositary Shares | $40.11M | — | $1.03 | ▼ 4.63% | $0.0035$0.037 |
| HYPD Hyperion DeFi Inc. Common Stock | $40.47M | 7.24 | $2.84 | ▼ 9.84% | $2.34$9.13 |
| PDSB PDS Biotechnology Corporation Common Stock | $41.78M | — | $1.13 | ▼ 13.08% | $0.1952$1.79 |
| APLM Apollomics Inc. Class A Ordinary Shares | $37.33M | — | $21.1 | ▲ 0.48% | $10.01$42.12 |
| CRVO CervoMed Inc. Common Stock | $37.33M | — | $2.24 | ▼ 0.44% | $2.13$10 |
| IXHL Incannex Healthcare Inc. Common Stock | $37.21M | — | $2.82 | ▼ 2.08% | $2.49$14.91 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →Acquired
9.4K
Disposed
0
- Dan Benjamin Teleman · June 17, 2026 · Buy6.5K @ $3.1
- Dan Benjamin Teleman · April 22, 2026 · Buy2.9K @ $3.76
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Nasus Pharma Enrolls First Patient in Phase 1 NS003 Study
Nasus Pharma has announced the enrollment and dosing of the first patient in a Phase 1 clinical study for NS003, an intranasal formulation of ondansetron. This marks a key early-stage milestone for the company's development pipeline. The stock is currently trading near its 52-week high, reflecting ongoing interest in these clinical updates.
Nasus Pharma Enrolls First Patient in Phase 1 NS003 Study. Nasus Pharma has announced the enrollment and dosing of the first patient in a Phase 1 clinical study for NS003, an intranasal formulation of ondansetron. This marks a key early-stage milestone for the company's development pipeline. The stock is currently trading near its 52-week high, reflecting ongoing interest in these clinical updates.